Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...

Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S ...

Hims & Hers Health (HIMS) lays off 4% of its workforce as the company adjusted its strategy amid FDA scrutiny on copycat ...

Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

Investors are buying Hims & Hers Health ( HIMS 10.09%) stock hand over fist after the mail-order drugs company reported an earnings miss but a sales beat last night. But they're selling off shares of ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

To sustain momentum, Hims recently announced a deal with Novo Nordisk A/S (NYSE: NVO) to distribute branded Wegovy at ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

As of 11:20 a.m. ET, Hims & Hers stock is surging to 11.2% and beyond, whereas both Eli Lilly and Novo Nordisk stocks are down 3.2%. Hims & Hers reported a surge in sales in the first quarter of ...

Hims & Hers Health (NYSE:HIMS) recently saw a significant stock price increase, jumping 140% over the past month. This rise ...